Which has preferable valuation and earnings, KARD or PRLD?

Kardigan has higher earnings, but lower revenue than Prelude Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kardigan N/A N/A N/A N/A N/A Prelude Therapeutics $12.14M 24.12 -$99.50M -$0.73 N/A

Is KARD or PRLD more profitable?

Kardigan's return on equity of 0.00% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kardigan N/A N/A N/A Prelude Therapeutics N/A -75.35% -44.39%

Does the media favor KARD or PRLD?

In the previous week, Kardigan had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 5 mentions for Kardigan and 3 mentions for Prelude Therapeutics. Kardigan's average media sentiment score of 0.22 beat Prelude Therapeutics' score of 0.21 indicating that Kardigan is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kardigan 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prelude Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PRLD or TYRA more profitable?

Tyra Biosciences' return on equity of -46.39% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -75.35% -44.39% Tyra Biosciences N/A -46.39% -43.07%

Does the media favor PRLD or TYRA?

In the previous week, Prelude Therapeutics and Prelude Therapeutics both had 3 articles in the media. Tyra Biosciences' average media sentiment score of 0.67 beat Prelude Therapeutics' score of 0.21 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tyra Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PRLD or MAZE more profitable?

Maze Therapeutics' return on equity of -34.94% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -75.35% -44.39% Maze Therapeutics N/A -34.94% -30.18%

Does the media refer more to PRLD or MAZE?

In the previous week, Maze Therapeutics had 9 more articles in the media than Prelude Therapeutics. MarketBeat recorded 12 mentions for Maze Therapeutics and 3 mentions for Prelude Therapeutics. Maze Therapeutics' average media sentiment score of 0.57 beat Prelude Therapeutics' score of 0.21 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Maze Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AVBP or PRLD more profitable?

ArriVent BioPharma's return on equity of -50.26% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -50.26% -46.66% Prelude Therapeutics N/A -75.35% -44.39%

Does the media refer more to AVBP or PRLD?

In the previous week, Prelude Therapeutics had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 3 mentions for Prelude Therapeutics and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.90 beat Prelude Therapeutics' score of 0.21 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prelude Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is OMER or PRLD more profitable?

Prelude Therapeutics' return on equity of -75.35% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -164.92% 69.41% Prelude Therapeutics N/A -75.35% -44.39%

Does the media prefer OMER or PRLD?

In the previous week, Omeros and Omeros both had 3 articles in the media. Omeros' average media sentiment score of 0.67 beat Prelude Therapeutics' score of 0.21 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prelude Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Prelude Therapeutics (PRLD) Competitors

$3.67 -0.12 (-3.17%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.66 0.00 (-0.14%)

As of 10/2/2026 07:30 PM Eastern

Compare

PRLD vs. KARD, TYRA, MAZE, AVBP, and OMER

Should you buy Prelude Therapeutics stock or one of its competitors? Prelude Therapeutics's main competitors and comparable companies include Kardigan (KARD), Tyra Biosciences (TYRA), Maze Therapeutics (MAZE), ArriVent BioPharma (AVBP), and Omeros (OMER). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Prelude Therapeutics compare to Kardigan?

Kardigan (NASDAQ:KARD) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

In the previous week, Kardigan had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 5 mentions for Kardigan and 3 mentions for Prelude Therapeutics. Kardigan's average media sentiment score of 0.22 beat Prelude Therapeutics' score of 0.21 indicating that Kardigan is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kardigan	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prelude Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kardigan has higher earnings, but lower revenue than Prelude Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kardigan	N/A	N/A	N/A	N/A	N/A
Prelude Therapeutics	$12.14M	24.12	-$99.50M	-$0.73	N/A

Kardigan's return on equity of 0.00% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kardigan	N/A	N/A	N/A
Prelude Therapeutics	N/A	-75.35%	-44.39%

79.7% of Prelude Therapeutics shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Kardigan presently has a consensus target price of $42.25, indicating a potential upside of 185.67%. Prelude Therapeutics has a consensus target price of $8.75, indicating a potential upside of 138.42%. Given Kardigan's higher possible upside, research analysts clearly believe Kardigan is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kardigan	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Kardigan beats Prelude Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Prelude Therapeutics compare to Tyra Biosciences?

Prelude Therapeutics (NASDAQ:PRLD) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Prelude Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 138.42%. Tyra Biosciences has a consensus price target of $46.89, suggesting a potential upside of 129.51%. Given Prelude Therapeutics' higher possible upside, analysts clearly believe Prelude Therapeutics is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Prelude Therapeutics and Prelude Therapeutics both had 3 articles in the media. Tyra Biosciences' average media sentiment score of 0.67 beat Prelude Therapeutics' score of 0.21 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tyra Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prelude Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

Prelude Therapeutics has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	24.12	-$99.50M	-$0.73	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

Tyra Biosciences' return on equity of -46.39% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-75.35%	-44.39%
Tyra Biosciences	N/A	-46.39%	-43.07%

Summary

Prelude Therapeutics and Tyra Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Prelude Therapeutics compare to Maze Therapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Maze Therapeutics' return on equity of -34.94% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-75.35%	-44.39%
Maze Therapeutics	N/A	-34.94%	-30.18%

79.7% of Prelude Therapeutics shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Prelude Therapeutics has higher earnings, but lower revenue than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	24.12	-$99.50M	-$0.73	N/A
Maze Therapeutics	$167.50M	8.77	-$131.12M	-$2.52	N/A

Prelude Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

In the previous week, Maze Therapeutics had 9 more articles in the media than Prelude Therapeutics. MarketBeat recorded 12 mentions for Maze Therapeutics and 3 mentions for Prelude Therapeutics. Maze Therapeutics' average media sentiment score of 0.57 beat Prelude Therapeutics' score of 0.21 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maze Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prelude Therapeutics presently has a consensus price target of $8.75, indicating a potential upside of 138.42%. Maze Therapeutics has a consensus price target of $63.40, indicating a potential upside of 139.88%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maze Therapeutics is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08

Summary

Maze Therapeutics beats Prelude Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Prelude Therapeutics compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

ArriVent BioPharma currently has a consensus target price of $44.86, suggesting a potential upside of 58.67%. Prelude Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 138.42%. Given Prelude Therapeutics' higher probable upside, analysts clearly believe Prelude Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Prelude Therapeutics has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A
Prelude Therapeutics	$12.14M	24.12	-$99.50M	-$0.73	N/A

In the previous week, Prelude Therapeutics had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 3 mentions for Prelude Therapeutics and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.90 beat Prelude Therapeutics' score of 0.21 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prelude Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ArriVent BioPharma has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

ArriVent BioPharma's return on equity of -50.26% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-50.26%	-46.66%
Prelude Therapeutics	N/A	-75.35%	-44.39%

Summary

Prelude Therapeutics beats ArriVent BioPharma on 9 of the 14 factors compared between the two stocks.

How does Prelude Therapeutics compare to Omeros?

Omeros (NASDAQ:OMER) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Prelude Therapeutics' return on equity of -75.35% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
Prelude Therapeutics	N/A	-75.35%	-44.39%

Omeros has a beta of 2.57, indicating that its stock price is 157% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

48.8% of Omeros shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 10.5% of Omeros shares are owned by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Omeros currently has a consensus price target of $34.00, suggesting a potential upside of 82.70%. Prelude Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 138.42%. Given Prelude Therapeutics' higher probable upside, analysts clearly believe Prelude Therapeutics is more favorable than Omeros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Omeros has higher earnings, but lower revenue than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$1.28	14.54
Prelude Therapeutics	$12.14M	24.12	-$99.50M	-$0.73	N/A

In the previous week, Omeros and Omeros both had 3 articles in the media. Omeros' average media sentiment score of 0.67 beat Prelude Therapeutics' score of 0.21 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prelude Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Omeros beats Prelude Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Prelude Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRLD vs. The Competition

Export

Metric	Prelude Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$292.88M	$3.87B	$7.14B	$13.22B
Dividend Yield	N/A	3.64%	2.53%	16.78%
P/E Ratio	N/A	13.13	275.97	26.04
Price / Sales	24.12	1,430.61	672.86	109.50
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	3.37	16.63	10.93	6.31
Net Income	-$99.50M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-5.41%	-2.99%	-2.00%	-1.66%
1 Month Performance	-30.10%	-10.60%	-6.15%	-4.50%
1 Year Performance	149.66%	19.44%	7.44%	2.06%

Prelude Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRLD Prelude Therapeutics	2.1571 of 5 stars	$3.67 -3.2%	$8.75 +138.4%	+154.9%	$292.88M	$12.14M	N/A	79	News Coverage
KARD Kardigan	3.1968 of 5 stars	$16.28 -0.1%	$42.25 +159.5%	N/A	$1.52B	N/A	N/A	241	News Coverage Positive News
TYRA Tyra Biosciences	3.3501 of 5 stars	$25.27 -1.5%	$46.89 +85.5%	+52.6%	$1.51B	N/A	N/A	87
MAZE Maze Therapeutics	2.6883 of 5 stars	$27.02 +20.7%	$66.00 +144.2%	-0.3%	$1.50B	$167.50M	N/A	141	News Coverage Negative News Insider Trade Gap Up High Trading Volume
AVBP ArriVent BioPharma	2.6803 of 5 stars	$30.36 +2.1%	$44.86 +47.8%	+50.1%	$1.50B	N/A	N/A	77	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRLD) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prelude Therapeutics (PRLD) Competitors

PRLD vs. KARD, TYRA, MAZE, AVBP, and OMER

How does Prelude Therapeutics compare to Kardigan?

Summary

How does Prelude Therapeutics compare to Tyra Biosciences?

Summary

How does Prelude Therapeutics compare to Maze Therapeutics?

Summary

How does Prelude Therapeutics compare to ArriVent BioPharma?

Summary

How does Prelude Therapeutics compare to Omeros?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prelude Therapeutics (PRLD) Competitors

PRLD vs. KARD, TYRA, MAZE, AVBP, and OMER

How does Prelude Therapeutics compare to Kardigan?

Does the media favor KARD or PRLD?

Which has preferable valuation and earnings, KARD or PRLD?

Is KARD or PRLD more profitable?

Do insiders and institutionals believe in KARD or PRLD?

Do analysts prefer KARD or PRLD?

Summary

How does Prelude Therapeutics compare to Tyra Biosciences?

Do analysts rate PRLD or TYRA?

Do insiders & institutionals hold more shares of PRLD or TYRA?

Does the media favor PRLD or TYRA?

Which has more risk and volatility, PRLD or TYRA?

Which has better valuation and earnings, PRLD or TYRA?

Is PRLD or TYRA more profitable?

Summary

How does Prelude Therapeutics compare to Maze Therapeutics?

Is PRLD or MAZE more profitable?

Do insiders and institutionals have more ownership in PRLD or MAZE?

Which has stronger valuation & earnings, PRLD or MAZE?

Which has more risk and volatility, PRLD or MAZE?

Does the media refer more to PRLD or MAZE?

Do analysts recommend PRLD or MAZE?

Summary

How does Prelude Therapeutics compare to ArriVent BioPharma?

Do analysts recommend AVBP or PRLD?

Which has better earnings and valuation, AVBP or PRLD?

Does the media refer more to AVBP or PRLD?

Do insiders & institutionals have more ownership in AVBP or PRLD?

Which has more volatility and risk, AVBP or PRLD?

Is AVBP or PRLD more profitable?

Summary

How does Prelude Therapeutics compare to Omeros?

Is OMER or PRLD more profitable?

Which has more risk & volatility, OMER or PRLD?

Do insiders & institutionals have more ownership in OMER or PRLD?

Do analysts prefer OMER or PRLD?

Which has stronger earnings and valuation, OMER or PRLD?

Does the media prefer OMER or PRLD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools